The purpose of this study is to investigate borderline resectable pancreatic adenocarcinoma.
This study evaluates the impact and effectiveness of adding high-dose stereotactic body radiotherapy to preoperative chemotherapy. It seeks to understand if this combination can improve treatment outcomes for patients.
- Who can participate: Adults over 18 years with a confirmed diagnosis of pancreatic adenocarcinoma that is borderline resectable can participate. Participants must have good performance status and meet specific health criteria, including no prior treatment for pancreatic cancer.
- Study details: Participants will receive chemotherapy before surgery. Some will also receive high-dose radiotherapy. A placebo is not used in this study.